Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Issue 6 (11th May 2020)

• Record Type: Journal Article
• Authors: Pine, Alexander B.; Chokr, Nora; Stahl, Maximilian; Steensma, David P.; Sekeres, Mikkael A.; Litzow, Mark R.; Luger, Selina M.; Stone, Richard M.; Greenberg, Peter L.; Bejar, Rafael; Bewersdorf, Jan P.; Gore, Steven D.; Zeidan, Amer M.
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 6(2020)
• Page Start: 1455
• Page End: 1464
• Publication Date: 2020-05-11
• Subjects: Myelodysplastic syndrome -- next-generation sequencing -- mutations -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1723013
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Next-generation sequencing (NGS) is increasingly employed for diagnosis, risk stratification, and management of patients with myelodysplastic syndrome (MDS). We aimed to describe beliefs and practice patterns among providers who treat MDS patients with respect to the utility of NGS in diagnosis, risk stratification, prognosis, and treatment decisions at various points along the disease trajectory, response assessment, and development of institutional guidelines for MDS-specific molecular profiling. Using a 23-question web-based survey in May–June 2018, we identified a widespread use of molecular profiling with MDS-specific panels ( N = 53; 39%) and general panels including MDS-related genes ( N = 63; 47%), with the majority done at diagnosis (92%). We found substantial variations in genes tested in assays, providers beliefs, practices, testing logistics, and interpretation of results, and recognized multiple challenges limiting a wider utilization of molecular profiling. High-quality data are needed to develop evidence-based guidelines for the role of NGS in the care of MDS patients.